Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival

Table 6 Univariate and multivariate analyses of clinical factors related to overall survival in non-small cell lung carcinoma

Factor	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age, yr
< 75	1			1
≥ 75	0.520	0.277-0.976	0.042	0.658	0.345-1.253	0.203
Sex
Male	1
Female	1.301	0.845-2.003	0.233
BMI, kg/m2
Underweight (< 18.5)	1			1
Normal (18.5-24.9)	0.527	0.316-0.878	0.014	0.635	0.377-1.067	0.086
Overweight (> 25.0)	0.394	0.195-0.795	0.009	0.506	0.250-1.040	0.064
Stage
III	1			1
IV	2.447	1.227-4.881	0.011	2.182	1.085-4.387	0.029
ECOG PS
0-1	1			1
2-3	15.197	8.486-27.214	< 0.001	12.772	7.067-23.085	< 0.001
GI-irAE
Continued administration of ICIs	1
Discontinued administration of ICIs	0.904	0.165-4.945	0.907
Non-GI-irAEs	1.334	0.489-3.642	0.574

BMI: Body mass index; CI: Confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status; GI-irAE: Gastrointestinal-immune-related adverse event; HR: Hazard ratio; ICI: Immune checkpoint inhibitor.